Predictive Oncology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a POAI research report →
Price Chart
About the company
Predictive Oncology Inc. (POAI), an organization driven by expertise and data, is dedicated to pioneering individualized cancer treatments through the application of artificial intelligence, primarily within the United States. The company conducts its operations across four distinct divisions: Helomics, zPREDICTA, Soluble, and Skyline.
- CEO
- Raymond F. Vennare
- IPO
- 2010
- Employees
- 23
- HQ
- Pittsburgh, MN, US
Get TickerSpark's AI analysis on POAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.57M
- P/E
- -0.07
- Fwd P/E
- 4.09
- PEG
- 0.00
- P/S
- 37.66
- P/B
- 6.18
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
- Gross Margin
- 1.65%
- Op Margin
- -953.64%
- Net Margin
- -7769.79%
- ROE
- -2273.26%
- ROIC
- -49.53%
Latest fiscal year · YoY change
- Revenue
- $125.28K-92.3%
- Gross Profit
- $52.66K-93.4%
- Op Income
- $-28,425,165
- Net Income
- $-233,095,203-1810.4%
- EPS
- $-13.37-496.9%
- OCF Growth
- +16.7%
- FCF Growth
- +16.8%
- 52W High
- $45.90
- 52W Low
- $1.21
- 50D MA
- $8.42
- 200D MA
- $13.27
- Beta
- 1.35
- RSI (14)
- 45
- Avg Volume
- 141.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Axe Compute said Q1 was still in transition, but management pointed to a large signed compute build and a $4.3 billion pipeline as the setup for much stronger revenue recognition ahead.· May 18, 2026
- Q1 2026 revenue was $35,000, with a net loss of $7.7 million and $4.3 million of that tied to noncash digital-asset mark-to-market losses.
- Management said the business is shifting toward Compute Services, with early traction showing up in contract liabilities and receivables from customer prepayments.
- The company highlighted a $260 million, 36-month deal for 2,304 NVIDIA B300s, with targeted deployment in Q3 2026 and about $21 million per quarter of revenue once live.
- Pipeline detail was aggressive: 45 advanced prospects, over 36,000 GPUs, about 72% Blackwell-family requests, and over $4.3 billion in total contract value.
- CEO Chris Miglino said he expects about $1 billion in transactions this year and said the model should start showing more clearly in Q2 and Q3.
For Q1 2026, Axe Compute reported revenue of $35,000 versus $110,000 in Q1 2025. Net loss was $7.7 million, or $0.36 per share, including $4.3 million in noncash losses on digital assets; excluding that mark-to-market impact, underlying operating loss was about $3.4 million. Total operating costs and expenses were $3.5 million versus $2.4 million a year ago, and general and administrative expense was $2.9 million, up about $1.1 million year over year. Cash and cash equivalents were $6.9 million at March 31, 2026, down from $10.8 million at December 31, 2025, while digital asset holdings were $20.2 million and digital asset receivable was $15.4 million. Looking ahead, management said the $260 million contract is a 36-month agreement with targeted deployment in Q3 2026 and expected revenue recognition of around $21 million per quarter once the cluster goes live.
Christopher Miglino framed Axe as a company that helps customers get AI compute on their terms, rather than forcing them into hyperscaler constraints around timing, location, and architecture. He emphasized the company’s two-track model: immediate-access inventory and larger dedicated build-outs, both intended to create owned infrastructure assets that can be redeployed after customer terms end. His tone was highly optimistic, stressing that the first large deal has already opened a “floodgate” of opportunities and that he expects the business to start showing through in the financials in the second and third quarters.
Jeremy Yaukey-Witter said Q1 reflected a transitional period with two segments and several noncash items, especially the $4.3 million digital-asset fair value loss that drove much of the $7.7 million net loss. He pointed to contract liabilities rising from $144,000 to $786,000, with about $650,000 tied to Compute Services, as evidence of customer prepayments and traction late in the quarter. He also noted cash used in operating activities of $3.7 million, cash and equivalents of $6.9 million, and digital asset holdings of $20.2 million plus a $15.4 million digital asset receivable tied to locked Aethir tokens vesting through December 2028.
There was no traditional analyst Q&A section in the transcript; the discussion was mainly management presentations. The main investor concerns addressed were why Q1 financials looked small versus the company’s narrative and how much of the loss was noncash, and management answered by separating digital-asset mark-to-market effects from underlying operating loss. Management also tried to clarify that the $4.3 billion pipeline is not committed revenue, but a set of qualified prospects, and that not all of it will close.
The bull case on this call is that Axe says it has already moved from concept to signed, long-duration enterprise compute contracts with meaningful recurring economics. Management highlighted a $260 million deal, a $4.3 billion pipeline, and a model that should add owned assets to the balance sheet while creating future cash flow and revenue.
The bear case is that reported Q1 operating results were still extremely small, with only $35,000 of revenue and a $7.7 million loss, while cash fell to $6.9 million. Much of the current equity story depends on execution: the large contract is not yet live, the pipeline is not committed, and management itself said Q1 was not representative of the business and that the financials should improve later in the year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 726.08K
- Float Shares
- 720.10K
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 17.91K | ▲ 17.91K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Blacher Joshua | other | 9,389 |
| Nov 28, 25 | Vennare Raymond F | other | 2,373 |
| Oct 7, 25 | Matthews Shawn | other | 0 |
| Oct 8, 25 | McLaughlin Thomas Louis | other | 0 |
| Sep 9, 25 | CHUNG-WELCH NANCY | other | 64,680 |
| Sep 9, 25 | HANDLEY DANIEL E | other | 64,680 |
| Sep 9, 25 | Hawryluk Matthew | other | 64,680 |
| Sep 9, 25 | Rao Veena | other | 64,680 |
| Sep 9, 25 | ST. CLAIR GREGORY SR | other | 64,680 |
| Sep 9, 25 | Nuzum Charles Lee Sr | other | 64,680 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our POAI coverage
Recent articles, reports, and earnings notes.
No research on POAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate POAI report →Predictive Oncology Q2 Earnings Call Highlights
defenseworld.net · Aug 19
Predictive Oncology (NASDAQ:POAI) Stock Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
defenseworld.net · Apr 21
Predictive Oncology Q4 Earnings Call Highlights
defenseworld.net · Apr 3
Predictive Oncology (NASDAQ:POAI) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened
defenseworld.net · Mar 19
Predictive Oncology (NASDAQ:POAI) versus Mitesco (OTCMKTS:MITI) Head-To-Head Comparison
defenseworld.net · Feb 10
Financial Analysis: Predictive Oncology (NASDAQ:POAI) and Healthcare Triangle (NASDAQ:HCTI)
defenseworld.net · Jan 30
Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened
defenseworld.net · Jan 10
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
globenewswire.com · Dec 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.